The present invention addresses the problem of producing an anti-CDH3 humanized antibody having lower immunogenicity and provide an anti-CDH3 humanized antibody-drug conjugate using the same, said anti-CDH3 humanized antibody-drug conjugate being capable of more efficiently killing CDH3-expressing cancer cells. Provided is an anti-CDH3 humanized antibody-drug conjugate produced by linking an anti-CDH3 humanized antibody to a cytotoxic drug, wherein: the anti-CDH3 humanized antibody comprises complementarity determining region sequences originated from the heavy chain variable region of an antibody that is produced by a cell (Deposition No. NITE BP-1536) and complementarity determining region sequences originated from the light chain variable region thereof； the framework region sequences in the heavy chain variable region comprise a heavy chain human subgroup III consensus framework sequence or a human germ line sequence selected at the optimum alignment； and the framework region sequences in the light chain variable region include a light chain human ? subgroup I consensus framework sequence or a human germ line sequence selected at the optimum alignment.
